Impact of combination antimicrobial therapy on mortality risk for critically ill Patients with carbapenem-resistant bacteremia

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 7, 2015, Pages 3748-3753

  Bass, Stephanie N ^a   Bauer, Seth R ^a   Neuner, Elizabeth A ^a   Lam, Simon W ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CARBAPENEM DERIVATIVE; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; GENTAMICIN; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; TIGECYCLINE; TOBRAMYCIN; ANTIINFECTIVE AGENT;

ACINETOBACTER BAUMANNII; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; APACHE; ARTICLE; CARBAPENEM RESISTANT BACTEREMIA; CASE CONTROL STUDY; CHARLSON COMORBIDITY INDEX; CONTROLLED STUDY; CRITICAL ILLNESS; CRITICALLY ILL PATIENT; FEMALE; GRAM NEGATIVE SEPSIS; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SURVIVAL RATE; BACTEREMIA; COMBINATION DRUG THERAPY; GRAM-NEGATIVE BACTERIAL INFECTIONS; INTENSIVE CARE UNIT; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; RETROSPECTIVE STUDY; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; BETA-LACTAM RESISTANCE; CARBAPENEMS; CASE-CONTROL STUDIES; CRITICAL ILLNESS; DRUG THERAPY, COMBINATION; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INTENSIVE CARE UNITS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL RATE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 84935849677     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00091-15     Document Type: Article

References (34)

1. Gupta N, Limbago BM, Patel JB, Kallen AJ. 2011. Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. Clin Infect Dis 53:60-67. http://dx.doi.org/10.1093/cid/cir202.
2. Rhomberg PR, Jones RN. 2009. Summary trends for the Meropenem Yearly Susceptibility Test Information Collection Program: a 10-year experience in the United States (1999-2008). Diagn Microbiol Infect Dis 65:414-426. http://dx.doi.org/10.1016/j.diagmicrobio.2009.08.020.
3. Nguyen M, Eschenauer GA, Bryan M, O'Neil K, Furuya EY, Della-Latta P, Kubin CJ. 2010. Carbapenem-resistant Klebsiella pneumoniae bacteremia: factors correlated with clinical and microbiologic outcomes. Diagn Microbiol Infect Dis 67:180-184. http://dx.doi.org/10.1016/j.diagmicrobio.2010.02.001.
4. Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. 2008. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 29:1099-1106. http://dx.doi.org/10.1086/592412.
5. Schwaber MJ, Klarfeld-Lidji S, Navon-Venezia S, Schwartz D, Leavitt A, Carmeli Y. 2008. Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob Agents Chemother 52:1028-1033. http://dx.doi.org/10.1128/AAC.01020-07.
6. Sheng WH, Liao CH, Lauderdale TL, Ko WC, Chen YS, Liu JW, Lau YJ, Wang LH, Liu KS, Tsai TY, Lin SY, Hsu MS, Hsu LY, Chang SC. 2010. A multicenter study of risk factors and outcome of hospitalized patients with infections due to carbapenem-resistant Acinetobacter baumannii. Int J Infect Dis 14:e764-e769. http://dx.doi.org/10.1016/j.ijid.2010.02.2254.
7. Lautenbach E, Synnestvedt M, Weiner MG, Bilker WB, Vo L, Schein J, Kim M. 2010. Imipenem resistance in Pseudomonas aeruginosa: emergence, epidemiology, and impact on clinical and economic outcomes. Infect Control Hosp Epidemiol 31:47-53. http://dx.doi.org/10.1086/649021.
8. Ben-David D, Kordevani R, Keller N, Tal I, Marzel A, Gal-Mor O, Maor Y, Rahav G. 2012. Outcome of carbapenem resistant Klebsiella pneumoniae bloodstream infections. Clin Microbiol Infect 18:54-60. http://dx.doi.org/10.1111/j.1469-0691.2011.03478.x.
9. Borer A, Saidel-Odes L, Riesenberg K, Eskira S, Peled N, Nativ R, Schlaeffer F, Sherf M. 2009. Attributable mortality rate for carbapenem-resistant Klebsiella pneumoniae bacteremia. Infect Control Hosp Epidemiol 30:972-976. http://dx.doi.org/10.1086/605922.
10. Carmeli Y, Akova M, Cornaglia G, Daikos GL, Garau J, Harbarth S, Rossolini GM, Souli M, Giamarellou H. 2010. Controlling the spread of carbapenemase-producing Gram-negatives: therapeutic approach and infection control. Clin Microbiol Infect 16:102-111. http://dx.doi.org/10.1111/j.1469-0691.2009.03115.x.
11. Qureshi ZA, Paterson DL, Potoski BA, Kilayko MC, Sandovsky G, Sordillo E, Polsky B, Adams-Haduch JM, Doi Y. 2012. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother 56:2108-2113. http://dx.doi.org/10.1128/AAC.06268-11.
12. Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Tumietto F, Marchese A, Spanu T, Ambretti S, Ginocchio F, Cristini F, Losito AR, Tedeschi S, Cauda R, Bassetti M. 2012. Predictors of mortality in blood-stream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis 55:943-950. http://dx.doi.org/10.1093/cid/cis588.
13. Zarkotou O, Pournaras S, Tselioti P, Dragoumanos V, Pitiriga V, Ranellou K, Prekates A, Themeli-Digalaki K, Tsakris A. 2011. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin Microbiol Infect 17:1798-1803. http://dx.doi.org/10.1111/j.1469-0691.2011.03514.x.
14. Daikos GL, Markogiannakis A. 2011. Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems? Clin Microbiol Infect 17:1135-1141. http://dx.doi.org/10.1111/j.1469-0691.2011.03553.x.
15. van Belkum A, Halimi D, Bonetti EJ, Renzi G, Cherkaoui A, Sauvonnet V, Martelin R, Durand G, Chatellier S, Zambardi G, Engelhardt A, Karlsson A, Schrenzel J. 2015. Meropenem/colistin synergy testing for multidrug-resistant Acinetobacter baumannii strains by a two-dimensional gradient technique applicable in routine microbiology. J Antimicrob Chemother 70:167-172. http://dx.doi.org/10.1093/jac/dku342.
16. Clinical and Laboratory Standards Institute. 2011. Performance standards for antimicrobial susceptibility testing; 21st informational supplement. CLSI document M100-S21. Clinical and Laboratory Standards Institute, Wayne, PA.
17. Lee K, Chong Y, Shin HB, Kim YA, Yong D, Yum JH. 2001. Modified Hodge and EDTA-disk synergy tests to screen metallo-β-lactamase-producing strains of Pseudomonas and Acinetobacter species. Clin Microbiol Infect 7:88-91. http://dx.doi.org/10.1046/j.1469-0691.2001.00204.x.
18. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G, SCCM/ESICM/ACCP/ATS/SIS. 2003. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 31:1250-1256. http://dx.doi.org/10.1097/01.CCM.0000050454.01978.3B.
19. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. 1985. APACHE II: a severity of disease classification system. Crit Care Med 13:818-829. http://dx.doi.org/10.1097/00003246-198510000-00009.
20. Charlson ME, Pompei P, Ales KL, MacKenzie CR. 1987. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373-383. http://dx.doi.org/10.1016/0021-9681(87)90171-8.
21. Ferreira FL, Bota DP, Bross A, Melot C, Vincent JL. 2001. Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA 286:1754-1758. http://dx.doi.org/10.1001/jama.286.14.1754.
22. Moore CL, Osaki-Kiyan P, Haque NZ, Perri MB, Donabedian S, Zervos MJ. 2012. Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study. Clin Infect Dis 54:51-58. http://dx.doi.org/10.1093/cid/cir764.
23. European Committee on Antimicrobial Susceptibility Testing. 2011. Breakpoint tables for interpretation of MICs and zone diameters. European Committee on Antimicrobial Susceptibility Testing, Basel, Switzerland. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST-files/Disk-test-documents/EUCAST-breakpoints-v1.3-pdf.pdf.
24. Neuner EA, Yeh JY, Hall GS, Sekeres J, Endimiani A, Bonomo RA, Shrestha NK, Fraser TG, van Duin D. 2011. Treatment and outcomes in carbapenem-resistant Klebsiella pneumoniae bloodstream infections. Diagn Microbiol Infect Dis 69:357-362. http://dx.doi.org/10.1016/j.diagmicrobio.2010.10.013.
25. Lopez-Cortes LE, Cisneros JM, Fernandez-Cuenca F, Bou G, Tomas M, Garnacho-Montero J, Pascual A, Martinez-Martinez L, Vila J, Pachon J, Rodriguez Bano J. 2014. Monotherapy versus combination therapy for sepsis due to multidrug-resistant Acinetobacter baumannii: analysis of a multicentre prospective cohort. J Antimicrob Chemother 69:3119-3126. http://dx.doi.org/10.1093/jac/dku233.
26. Paul M, Carmeli Y, Durante-Mangoni E, Mouton JW, Tacconelli E, Theuretzbacher U, Mussini C, Leibovici L. 2014. Combination therapy for carbapenem-resistant Gram-negative bacteria. J Antimicrob Chemother 69:2305-2309. http://dx.doi.org/10.1093/jac/dku168.
27. Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Kim EC, Oh MD, Choe KW. 2005. Bloodstream infections caused by antibiotic-resistant Gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob Agents Chemother 49:760-766. http://dx.doi.org/10.1128/AAC.49.2.760-766.2005.
28. Micek ST, Lloyd AE, Ritchie DJ, Reichley RM, Fraser VJ, Kollef MH. 2005. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother 49:1306-1311. http://dx.doi.org/10.1128/AAC.49.4.1306-1311.2005.
29. Zahar JR, Timsit JF, Garrouste-Orgeas M, Francais A, Vesin A, Descorps-Declere A, Dubois Y, Souweine B, Haouache H, Goldgran-Toledano D, Allaouchiche B, Azoulay E, Adrie C. 2011. Outcomes in severe sepsis and patients with septic shock: pathogen species and infection sites are not associated with mortality. Crit Care Med 39:1886-1895. http://dx.doi.org/10.1097/CCM.0b013e31821b827c.
30. Roberts JA, Lipman J. 2009. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 37:840-851. http://dx.doi.org/10.1097/CCM.0b013e3181961bff.
31. McKinnon PS, Paladino JA, Schentag JJ. 2008. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents 31:345-351. http://dx.doi.org/10.1016/j.ijantimicag.2007.12.009.
32. Tam VH, McKinnon PS, Akins RL, Rybak MJ, Drusano GL. 2002. Pharmacodynamics of cefepime in patients with Gram-negative infections. J Antimicrob Chemother 50:425-428. http://dx.doi.org/10.1093/jac/dkf130.
33. Pena C, Suarez C, Gozalo M, Murillas J, Almirante B, Pomar V, Aguilar M, Granados A, Calbo E, Rodriguez-Bano J, Rodriguez F, Tubau F, Martinez-Martinez L, Oliver A. 2012. Prospective multicenter study of the impact of carbapenem resistance on mortality in Pseudomonas aeruginosa bloodstream infections. Antimicrob Agents Chemother 56:1265-1272. http://dx.doi.org/10.1128/AAC.05991-11.
34. Kim SY, Jung JY, Kang YA, Lim JE, Kim EY, Lee SK, Park SC, Chung KS, Park BH, Kim YS, Kim SK, Chang J, Park MS. 2012. Risk factors for occurrence and 30-day mortality for carbapenem-resistant Acinetobacter baumannii bacteremia in an intensive care unit. J Korean Med Sci 27:939-947. http://dx.doi.org/10.3346/jkms.2012.27.8.939.